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Muscle’s structural composition is an important factor underlying muscle strength and physical function in older adults. There
is an increasing amount of research to support the clear disassociation between the loss of muscle lean tissue mass and strength
with aging. This disassociation implies that factors in addition to lean muscle mass are responsible for the decreases in strength
and function seen with aging. Intermuscular adipose tissue (IMAT) is a significant predictor of both muscle function and mobility
function in older adults and across a wide variety of comorbid conditions such as stroke, spinal cord injury, diabetes, and COPD.
IMAT is also implicated in metabolic dysfunction such as insulin resistance. The purpose of this narrative review is to provide a
review of the implications of increased IMAT levels in metabolic, muscle, and mobility function. Potential treatment options to
mitigate increasing levels of IMAT will also be discussed.
1. Introduction
The unique ability of adipose tissue to expand throughout
life and release a host of chemical messengers makes adipose
not only a distinctive tissue but also the largest endocrine
organ in the body [1]. In the last twenty years, a rapid
expansion of our understanding of this unique organ has
occurred.Once thought to be an inert storage depot for excess
calories, important only to energy homeostasis, we now know
that adipose tissue expresses and secretes a multitude of
hormones and proinflammatory cytokines thereby acting in
an autocrine, paracrine, and endocrine manner signaling
the heart, musculoskeletal, central nervous, and metabolic
systems [1–3]. Not all adipose depots are alike. Recent studies
have suggested that the location [4–8] and type [9] of excess
adipose tissue, rather than simply total body adiposity, may
be important in the systemic increase of circulating cytokines
and the rise in metabolic diseases such as diabetes [9–14] (for
a more complete review of the types and roles of adipose
tissue, see Wronska 2012 and Stehno-Bittel 2008) [1, 9].
Adipose tissue stored in subcutaneous depots, particularly
in the gluteal-femoral region, is a negative predictor of
metabolic syndrome and is cardioprotective [4–7, 15, 16].
However, adipose tissue stored in ectopic locations outside
of the subcutaneous tissue such as in the muscle, liver, and
abdominal cavity is linkedwith chronic inflammation [10, 17–
19], impaired glucose tolerance [4–6, 20, 21], increased total
cholesterol [8, 16, 22], and decreased strength andmobility in
older adults [23–31]. Advancing age results in a redistribution
of fat depots, despite stable or decreasing overall fat, with
adipose storage sites changing from subcutaneous locations
to themore harmful ectopic locations [3, 32, 33]. In particular,
intermuscular adipose tissue (IMAT), an ectopic fat depot
found beneath the fascia and within the muscles, may be of
specific interest to rehabilitation professionals.
IMAT has been studied in a variety of individuals with
metabolic [5, 6, 8, 14, 28, 34–36], orthopedic [37, 38], and
neurologic [39, 40] conditions commonly seen in rehabilita-
tive settings. High levels of IMAT are associated with insulin
resistance [5, 6, 8, 14, 28, 34–36], a loss of strength [23–31],
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and mobility dysfunction [23, 41–43]. High levels of IMAT
can be found in many patient populations, including, but
not restricted to, the paraspinal muscles of individuals with
chronic back pain [37, 38] and the locomotor muscles of
individuals diagnosed with HIV [44], spinal cord injury [39],
CVA [40], diabetes [6], and COPD [45]. Furthermore, older
adults with increased IMAT levels in the locomotor muscles
are known to experience increased levels of muscle weakness,
decreasedmobility function [23, 41–43], and an increased risk
of future mobility limitation [42, 43]. IMAT has potential
clinical implications that rehabilitation professionals should
recognize and attempt to manage in rehabilitation settings
when working with older adults and those with diseases and
disabilities associated with IMAT.
The purpose of this narrative review is to inform reha-
bilitation professionals about the potential metabolic, mus-
cle, and mobility associations of increased IMAT in the
locomotor muscles of adults. This review will focus on
three areas. First, the definition and measurement of IMAT
will be presented; second, the implications of increased
locomotor muscle IMAT in metabolism, muscle strength,
and mobility will be reviewed; and third, recommendations
for future research and treatment for adults with increased
levels of IMAT will be made. Literature targeted for this
review included peer reviewed cross-sectional, longitudinal,
epidemiologic, and clinical studies in adult humans.
2. Definitions and Measurements of IMAT
IMAT has been referred to in the literature by a variety of
names and definitions includingmyostasis, intermuscular fat,
intramuscular fat, and low density lean tissue. Intermuscular
fat is typically the broadest definition of fatty infiltration
in the muscle referring to storage of lipids in adipocytes
underneath the deep fascia ofmuscle.This includes the visible
storage of lipids in adipocytes located between the muscle
fibers (also termed intramuscular fat) and also between
muscle groups (literally intermuscular) [46] (See Figure 1).
While not frequently isolated as a separate fat depot by itself,
there also exists a smaller group of lipids stored within the
muscle cells themselves known as intramyocellular lipids or
IMCL; IMCL has been reviewed extensively elsewhere [47].
Increased levels of IMCL are found both in obese insulin
resistant individuals and in highly trained endurance athletes;
these paradoxical findings have led to the conclusion that
lipids stored within muscle cells are not always harmful to
the cell [47]. For the remainder of this review, the term
IMAT will refer to any measure of fat beneath the deep fascia
of the thigh, not including studies that have used methods
that independently quantify IMCLs (i.e., histochemical or
spectroscopic methods).
IMAT ismost commonlymeasured via computed tomog-
raphy (CT) or magnetic resonance imaging (MRI). While
IMAT has been quantified in numerous studies, it is not yet
routinely measured or quantified in clinical imaging studies.
CT scans have been extensively used to quantify IMAT in
numerous studies [5, 6, 10, 14, 20, 23, 28, 40, 42, 43, 48–
52] and were first described by Kelley et al. in 1991 [53].
CT is a fast imaging method that utilizes X-rays for an
indirect measurement of IMAT based on the tissue density
of an area. On a continuum of density where bone is the
most dense and fat is the least dense, lean muscle mass falls
between these two extremes. Lean tissue seen on a CT scan
can be further divided into areas of high-density lean tissue
and areas of low-density lean tissue. High-density lean is an
area where little fatty infiltration occurs, and low-density lean
tissue is an areawhere increased levels of adipocytes are found
between and within muscle fibers and result in decreased
density on CT scan. An individual with a higher proportion
of low-density lean is assumed to have increased levels of both
IMCL and IMAT. If the density of a muscle increases, or the
area of low-density lean decreases after an exercise program,
it is presumed that the exercise program has resulted in a loss
of both IMCL and IMAT.
With MRI, direct measurements of IMAT [46] can occur
without the use of harmful radiation; therefore, MRI is
increasingly used to quantify IMAT [25–27, 29–31, 35, 36,
39, 46, 54–65]. MRIs utilize the chemical properties of fat
and muscle to directly measure the amount of IMAT within
a region of interest [46]. However, while MRI studies of
IMAT avoid the use of harmful radiation, they do typically
require time-consuming manual segmentation for a region
of interest. This process can be difficult and less reliable
for small, irregularly shaped areas. Comparative studies of
MRI and CT have demonstrated that MRI has a higher
sensitivity than CT for identifying early fatty replacement
in muscle and that MRI, because it is not density based,
provides better anatomical details of soft tissue than CT
[46, 66, 67]. Studies comparing CT and MRI measurements
have generally shown good agreement and both methods
are acceptable precise measures of IMAT [68, 69]. The same
definition and method for measuring IMAT should be used
in pre- and poststudies. Both CT and MRI appear to be
appropriate and advanced techniques for measuring IMAT;
however, drawing conclusions concerning absolute amounts
of IMAT across studiesmay be difficult if differentmethods of
measurement are employed. Many studies have used slightly
different definitions of IMAT (i.e., adipose tissue in a muscle,
adipose tissue between muscles, or adipose tissue under the
fascia of the thigh), and conclusions drawn across studies
should be interpreted within this context.
3. IMAT and Metabolism
IMAT is positively associated with insulin resistance and
an increased risk of developing type 2 diabetes [5, 6, 8, 14,
28, 34–36] (Figure 2). The link between IMAT and insulin
resistance could be theoretically attributed to the relationship
of IMAT and BMI. Generally, as BMI increases so does
IMAT [7, 21, 23]. However, even when BMI is statistically
accounted for, IMAT remains a strong predictor of fasting
glucose and insulin levels in both younger [5] and older adults
[6, 22, 54], suggesting that these metabolic impairments are
not simply due to obesity alone. Compared to subcutaneous
fat, IMAT is a much smaller fat depot, accounting for as little
as 8% of the adipose tissue in the thigh [5]. Despite its small






Figure 1: Intermuscular fat is generally considered to be any fat (including the fat betweenmuscle groups and within amuscle) found beneath
the fascia of amuscle and is thewidest definition for fat beneath the fascia of amuscle. Intramuscular fat is the visible fat foundwithin amuscle.
Intermuscular is considered to be an ectopic fat depot similar to visceral adipose tissue (VAT) found in the abdomen.
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Figure 2: Muscle injury, obesity, age, disease status, and inactivity are all factors that are associated with increased levels of IMAT. Increased
levels of IMAT may also lead to a myriad of metabolic, muscle, and mobility dysfunctions.
size, IMAT is strongly associated with insulin sensitivity in
obese individuals [5]. It is currently unknown if IMAT acts
merely as a marker of metabolic dysfunction or if it may
have an intermediary or modifying role in insulin resistance.
Since IMAT sits in close proximity to the muscle fibers, it is
possible that IMAT may interact with muscle fibers through
a yet unknown pathway leading to muscle dysfunction and
insulin resistance [10, 26]. Muscle dysfunction may lead to
further inactivity and increased levels of IMAT precipitating
a cycle of increased IMAT, insulin resistance, and muscle
dysfunction.This close relationship between themuscle fibers
and IMAT becomes particularly important in populations
that are known to have increased IMAT, muscle dysfunction,
and insulin resistance including individuals with diabetes
[70] and survivors of stroke [28, 40] and spinal cord injury
[39, 57, 58].
After a stroke (CVA), muscle volume decreases and both
subcutaneous adipose tissue and IMAT increase in the paretic
limb [28, 40]. We noted that, in the paretic limb, the subcuta-
neous adipose depot was 6% higher and IMATwas increased
4% compared to the nonparetic limb in older stroke survivors
[28]. Similar to the findings in older adults with type 2
diabetes, a positive relationship also exists between IMAT
and fasting insulin levels in those post-CVA [28]. In this
study of 70 adult stroke survivors, we found that decreased
muscle attenuation (indicating increased IMAT levels) was
associated with increased fasting insulin levels [28]. Similar
results are found in those who have suffered a spinal cord
injury. One study found that thigh IMAT increased on
average 26% in just three months after a complete spinal
cord injury [39]. This large increase in IMAT accounted
for a 70% reduction in glucose tolerance in these same
individuals [39]. The strong relationship observed between
decreased glucose tolerance and increased IMAT postspinal
cord injury suggests that accumulation of IMAT may have
a deleterious effect on glucose homeostasis particularly in
those who are mobility limited. Further studies are necessary
to determine if IMAT plays a direct role in decreased
glucose tolerance or if it is only a marker of metabolic
dysfunction.
4 International Journal of Endocrinology
Despite not knowing the specific mechanism behind
IMAT’s potentially harmful influence onmuscle metabolism,
there are several lines of evidence that support this relation-
ship. Multiple authors have suggested that IMAT, an ectopic
fat depot similar to visceral adipose tissue, may release a host
of proinflammatory cytokines resulting in local inflammation
within themuscle [10, 26, 48, 65, 71]. Other ectopic fat depots,
such as those found in the liver or the abdomen, are known to
have increased systemic levels of proinflammatory cytokines
[72]. Beasley et al. also reported a relationship between the
amount of IMAT within the thigh and systemic measures
of proinflammatory cytokines, as measured in the serum
suggesting that IMAT may in fact be related to increased
whole body inflammation [10]. We reported for the 1st time
increased IMAT in the paretic leg of stroke survivors [40],
which we followed with our examination of skeletal muscle
TNF-a [73].We found that both IMAT [40] and inflammation
[73] are increased in the paretic leg of stroke survivors [28,
73]. However, to date, we are unaware of any published exam-
inations of the direct relationship between IMAT and the
local inflammatory environment within the muscle. Skeletal
muscle is the primary site for glucosemetabolism in the body.
While it is currently unknown by which mechanism IMAT
may act on metabolism, it does appear that a relationship
exists between increased levels of IMAT and decreased
whole body glucose metabolism particularly in those who
have suffered an injury that reduces muscle function. It is
theorized that the close proximity of IMAT to the muscle
fiber may impair the local muscle environment through
aforementioned increase in local proinflammatory cytokines
[10, 59], impaired blood flow [5, 8], or increasing the rate
of lipolysis within skeletal muscle resulting in an increased
concentration of glucose within the skeletal muscle itself,
leading to insulin resistance [5, 8].
4. IMAT and Muscle Function
The structural composition of muscle is an important factor
in its function [23]. It is nowwell established that a loss of lean
muscle mass in older adults does not directly translate into a
loss of strength [41, 74]. The Baltimore Longitudinal Study of
Aging found that while grip strength and muscle mass both
declined with age, older adults were weaker than the loss of
muscle mass alone would predict [74]. Similar results were
found in a 3-year longitudinal study of 1800 healthy older
adults. In this finding from the Health ABC Study, muscle
strength declined even in those individuals who gained lean
muscle mass. While lean mass decreased by approximately
1% a year, strength decreased up to 4% during the same time
period [41]. This clear dissociation between lean mass and
strength advocates for factors other than lean muscle mass
being responsible for the declines in muscle function seen
with aging. IMAT is one such factor that may impact the
muscle function losses that are associated with aging.
An emerging body of literature supports IMAT as a
significant predictor of both muscle and mobility function
in older adults suggesting that increased IMAT may at least
partially explain a loss of strength and mobility seen with
aging [23–31] (Figure 2). Older adults with higher levels of
IMAT in the legs have lower muscle strength [23, 30] as well
as muscle quality [23] or the force produced per unit of cross-
sectional area of muscle, as demonstrated by the two women
whose thigh images are presented in Figure 3. Decreases in
muscle quality may lead to difficulties in functional activities
[75] and several studies have also demonstrated that adults
with comorbid conditions such as COPD [45], stroke [28],
osteoarthritis [76], kidney disease [77], and cognitive decline
[78] demonstrate decreases in muscle quality. The relation-
ship of increased levels of IMAT and decreased strength and
muscle quality is reported inmultiple studies in the thigh [23]
and calf muscles [30], in healthy elders [23], and in adults
with comorbid conditions including diabetes and peripheral
neuropathy [30]. It is intriguing that this relationship does not
appear to be confined to older adults [26]. After 30 days of
single limb suspension, Manini et al. found that young (∼20
years) healthy individuals experienced an increase of 15–20%
in IMAT of both the calf and thigh muscles. This increase
in IMAT also exceeded the loss of lean tissue suggesting that
IMATwas not just merely “filling” the space left by lean tissue
atrophy [26].The increase in IMATalso accounted for a 4–6%
of loss of strength, again emphasizing that IMAT ismore than
an inert storage depot, but may also play a role in inactivity
related strength loss.
High levels of IMAT are also associated with decreased
activation of the quadriceps muscles in older adults [31]. We
found a moderate significant negative relationship between
IMAT and quadriceps muscle activation in a small sample of
older adults. Muscle activation, in this study, was quantified
by the central activation ratio, a measure of a muscle’s ability
to fully activate during a maximal effort voluntary isometric
contraction. It appears that not only may IMAT impair a
muscle’s ability to produce force but also it may actually
hinder the improvement inmuscle quality typically seen with
resistance training [59]. We examined changes in muscle
quality after 12 weeks (3x/week) of resistance training in
70 older adults with a history of falls and found that only
individuals with low amounts of IMAT in the thigh at the
start of training were able to significantly improve muscle
quality. Similar to the loss of muscle quality with high levels
of IMAT, a decrease in muscle activation in the presence
of high amounts of IMAT suggests that IMAT may be
partially responsible for inhibiting muscle force production
and improvements with strength training.
5. IMAT and Mobility Function
Perhaps even more important than the association between
IMAT andmuscle function is the relationship between IMAT
andmobility.There is an increasing amount of evidence link-
ing IMAT with mobility impairment in older adults [25, 27,
29, 30, 42, 43]. Increased levels of IMAT are associated with
decreased six-minute walk distance [27, 30, 79], decreased
gait speed [43], decreased physical performance [25, 30],
difficulty with repeated chair stands [43], and slower stair
descent and timed up and go tests [27]. This relationship has
consistently been reported in a variety of populations of older
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Subject 07 8.4 6.6 7.0 88.2 194.8
Subject 44 6.5 4.9 4.4 139.5 248.3
Difference 25% 24%29% 45% 45%
Lean: 99.5 cm2 Lean: 100.7 cm2
IMAT: 18.8 cm2 IMAT: 9.8 cm2
Figure 3: Two women with similar age, BMI, and levels of lean muscle mass but with differing levels of IMAT in a cross-sectional MRI image
of the thigh. Subject 7 has double the level of IMAT (black within themuscle) in her thigh as subject 44.While both women have similar levels
of lean tissue (seen in grey), they have different levels ofmobility andmuscle function.The increased levels of IMAT and decreasedmuscle and
mobility function of subject 7 are consistent with literature that reports that increased levels of IMAT are associated with decreased muscle
and mobility function.
adults including healthy elders [43], those with a history of
diabetes [25, 30], COPD [45], falls [27], and cancer [27].
IMAT is frequently associated with mobility function
evenwhen lean tissue is not suggesting that IMATmay in fact
be an important variable when referring to mobility function
in older adults [80]. IMAT is also predictive of futuremobility
limitations [42]. A large study of over 3000 older adults aged
70–79 followed up for two and one half years revealed that
individuals with the greatest amounts of baseline IMAT were
50 to 80%more likely to developmobility limitations over the
following two and one half years when compared with those
with the lowest levels of baseline IMAT [42].This finding was
consistent even after adjusting for baseline total body fat and
muscle strength.
High levels of IMAT may not only impair mobility but
also increase the risk for developing disability. Increased
levels of IMAT correlate with low bone mineral density and
an increased risk of hip fracture [81, 82]. IMAT levels of
the mid-thigh are noted to be a strong and independent
determinant of bone mineral density [82]. Additionally, the
Health ABC Study, a large longitudinal investigation of over
2500 individuals between the ages of 70 and 79 years, reported
a large increase in the risk for hip fracture with increased
IMAT [81]. A decrease of one standard deviation of muscle
density of the thigh as measured with CT conferred a 50%
increase in hip fracture risk [81]. Even after adjusting for bone
mineral density, an increase in IMAT raised the risk of a hip
fracture by 40% [81].
It is clear that increased levels of IMAT are associated
with decreased muscle and mobility function in older adults
but whether IMAT is a marker of muscle dysfunction or
whether it has a direct effect on muscle dysfunction is not
currently known. IMAT may act as an intermediary mod-
ifying preexisting pathological process as IMAT’s harmful
relationship with muscle and mobility function has been
theoretically attributed to an increase in proinflammatory
cytokines [10, 26, 48, 65, 71] similar to the attributed effects
of proinflammatory cytokines on metabolic function. Inter-
estingly, several authors have reported relationships between
increased proinflammatory cytokines and decreased muscle
[83, 84] and mobility function [85–87] that are strikingly
similar to those reported between IMAT and muscle and
mobility function [19].
IMAT may also be harmful to muscle and mobility
function due to mechanical changes in muscle that occur in
the presence of IMAT that can lead to changes in muscle
fiber orientation [56]. Studies of rotator cuff injuries suggest
that the loss of force in a muscle may be related to increased
levels of IMAT [56]. After a supraspinatus tear, elasticity of the
muscle decreases and passive tension of the supraspinatus is
increased.This decreased elasticity leads to a poorer ability to
actively generate force, resulting in a loss of maximal tension
of the muscle [88]. In addition to the loss of elasticity in
rotator cuff muscles, it has been hypothesized that excess
IMAT leads to an alteration in contractile fiber pennation
angle, hence resulting in an unfavorable mechanical angle
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and a concomitant reduction in force production [56, 89].We
are unaware of studies that have examined the effect of IMAT
on elasticity or of pennation angle in locomotor muscles.
While the impact of IMAT relative to elasticity or pennation
angle might be expected to be similar in other muscles,
the results from rotator cuff studies should be interpreted
cautiously due to differences in the muscle’s architecture and
function. Additionally, fatty infiltrate in rotator cuff muscles
follows a known musculotendinous injury, that is, a rotator
cuff tear. The cause of the increased fatty infiltration associ-
atedwithmanymetabolic or systemic diseases is not as easy to
pinpoint as there is no directmuscular injury. Future research
should elucidate the mechanisms behind increased IMAT
and decreased muscle and mobility function in older adults
and importantly should determine if minimizing IMAT is
accompanied by improved muscle and mobility function.
6. Aging, Weight Loss, Activity, and IMAT
Several authors have implied that IMAT is an unwanted but
inevitable consequence of aging as epidemiological, longitu-
dinal, and cross-sectional studies have reported significant
positive relationships between aging and IMAT [7, 48, 63, 90].
Some have theorized that whole body IMAT increases as
little as 9 grams/year [7] to as much as 70 grams/year [63].
The majority of studies examining the effects of aging on
increases in IMAT have been small and cross-sectional and
have failed to account for activity levels and disease status
or have investigated only a narrow age range. These caveats
call into question the definitive assertion that IMAT is an
inevitable consequence of aging [7, 63, 90]. In the largest
longitudinal study to date, Delmonico et al. followed up over
1600 older adults between the ages of 70 and 79 for 5-years
[48]. After accounting for race, weight changes, health status,
and activity levels, they found decreased thighmuscle density
even in those who lost weight or were weight stable over a
5-year period. However, it should be noted that increases in
IMAT were clearly influenced by increases in body weight as
those who gained the most body weight over five years also
gained themost IMAT. Furthermore, the study did not report
the reasons for loss of body weight (i.e., illness). Weight loss
due to intentional caloric restriction and exercise may have
a different influence on IMAT than weight loss due to illness
as numerous intervention studies have found that intentional
weight loss leads to decreases in IMAT [52, 62, 91, 92].
More recent work suggests that increases in IMAT may
be more a product of illness, disuse, or inactivity than aging
per se [24, 29, 64]. This is a clinically important finding as it
suggests that IMATmay be amenable to change via a physical
activity intervention (Figure 4). Longitudinal twin studies
have demonstrated that after 32 years of difference in activity
habits, inactive twins had 54% higher IMAT in their mid-
thigh compared to their more active twin [35]. High levels
of spasticity after spinal cord injury have also been shown
to protect against the accumulation of IMAT [57]. Further
support for the assertion that physical activity has a strong
influence on IMAT is found in studies of young, healthy
adults following periods of inactivity [26], when comparing
younger to older athletes [14, 64] and when comparing obese
active to inactive individuals [29]. After 30 days of single
limb suspension, a method of immobilizing one leg, young,
healthy adults demonstrate an increase of 15% IMAT in the
immobilized thigh and 20% in the calf [26]. In a cross-
sectional study examining master athletes from age 40 to
81 who consistently participated in high levels of physical
activity it was found that younger and older adults did not
differ in IMAT levels [26]. Even in a population of obese
adults with diabetes and peripheral neuropathy, conditions
known to be associated with increased IMAT, there still exists
a significant relationship between the number of steps taken
in a day and the volume of IMAT in the calf [29]. Tuttle et al.
reported that the average daily step count was able to explain
up to 19% of the variance in IMAT in the calf of older adults
with diabetes and peripheral neuropathy [29]. Based on these
studies, it appears that IMAT may be amenable to change via
increasing physical activity levels. However, themagnitude of
changes reported questions the clinical significance of these
changes. It may be that significant weight loss, via physical
activity or diet, may be necessary to achieve meaningful
changes in IMAT.
Multiple studies have examined the effects of diet, exer-
cise, or a combination of diet and exercise on IMAT [20, 22,
24, 51, 52, 55, 59, 61, 62, 91–100].Most have reported decreased
IMAT following intervention [20, 22, 51, 52, 55, 61, 62, 91–
94, 96, 97, 99]. The current general consensus among studies
examining changes in IMAT with weight loss alone or with
exercise is that weight loss is necessary to see significant
changes in IMAT [20, 51, 52, 55, 62, 91–93, 97]. However, it is
possible that exercise, whenperformed at a sufficient intensity
and duration to induce weight loss, is actually superior at
decreasing IMAT levels compared to weight loss induced by
reduced calorie intake [55, 62, 97]. Murphy et al. compared
the effects of exercise induced weight loss to weight loss
induced by calorie restriction alone in overweight adults
aged 50–60 [62]. They found that when exercise resulted in
weight loss, the loss of IMAT was two times greater than
calorie restriction alone. This finding is in agreement with
Christiansen et al. who found that the combination of calorie
restriction and exercise resulted in an 11% decrease in IMAT
while calorie restriction alone resulted in a 7% decrease in
IMAT [55]. While weight loss may be necessary to decrease
IMAT, this may not be a desirable option for some older
adults.Weight loss in frail, older adults with already low body
mass indexesmay be accompanied by loss ofmusclemass and
function and therefore may not result in a positive outcome.
There is currently a paucity of literature that examines the
effects of any intervention on IMAT in frail, older adults.
Most studies of IMAT to date have examined younger [22, 55,
92, 95, 96], obese, [22, 52, 55, 91–93], or overweight [20, 22,
51, 52, 62, 91, 94–96, 101] populations, making generalization
to frail, older adults difficult. Goodpaster et al. reported that
physical activity nearly ameliorated the increase in IMAT that
occurs with sedentary behavior in older adults with a mean
age of 76 years [24]. A modest walking program of 1-2 times
per week for as little as 30 minutes per session stabilized
IMAT accumulation in these individuals. In contrast, in this
same study, the control group that did not participate in any
International Journal of Endocrinology 7
Muscle 
- Increased muscle strength 
- Increased muscle quality 
Metabolic
- Increased insulin sensitivity
- Decreased inflammation
Mobility
- Increased gait speed







Figure 4: Exercise and weight loss may act to directly decrease IMAT, improve factors associated with increased IMAT such as obesity and
inactivity, and improve metabolic, muscle, and mobility dysfunction.
formal exercise program experienced an 18% gain in thigh
IMATover 12months [24].This suggests that physical activity
might mitigate the accumulation of IMAT in older adults.
However, only two small studies have found that increasing
physical activity, one through walking and the other through
resistance training, decreased IMAT in this population [93,
94]. We also found that resistance training decreased IMAT
in the thigh muscles of older adults (∼65 years) who had
a CVA [101]. This is a promising finding as it suggests that
IMATmay respond to physical activity interventions, even in
older adults with comorbid health conditions.However,more
research is needed to (1) verify these findings, (2) determine
the most effective method of reducing IMAT, and (3) assess
the clinical impact of doing so in older adults.
7. Future Directions and
Rehabilitation Considerations
More work is necessary to determine the role of increased
IMAT on metabolic, mobility, and muscle dysfunction. It
has not yet been determined if IMAT is merely a marker
of dysfunction or if it has some direct or indirect role
in modifying metabolic, muscle, and mobility function. If
IMAT does impair muscle activation, then using exercise as a
method to reduce IMATmayhave a limited effect particularly
in frail, older adults. Impaired muscle contraction may
minimize the muscles ability to mobilize and utilize IMAT
as a fuel source, and it is possible that a combination of
therapies will be necessary to reduce IMAT. This may be
particularly true in frail, older adults with limited ability or
need to change their body mass. The addition of electrical
stimulation to exercise may be one method to reduce IMAT
and improve muscle function. In a small study of nine
individuals with complete spinal cord injurywhich compared
the use of electrical stimulation on the quadriceps muscles
twice a week for 12 weeks combinedwith calorie restriction to
calorie restriction alone, the addition of electrical stimulation
was shown to significantly decrease IMAT [58]. While the
decrease in IMAT was still relatively small (approximately
3%); particularly noteworthy is the observation that the
calorie restriction group increased IMAT by 3% during this
same period of time [58]. The use of electrical stimulation
may result in increased muscle contraction and perhaps an
increased ability to use IMAT as a fuel source thus decreasing
IMAT within the muscle. This has yet to be explored and is
currently only speculative.
Another promising direction that may yield new thera-
peutic targets is research into the origins of IMAT. Studies
investigating the cellular origins of IMAT [102, 103] are
attempting to determine the cellular processes that precipitate
increased IMAT.While these origins are currently unknown,
if found to be similar to other ectopic fat depots such as those
found in the liver, pharmacological interventions used in
combination with exercise may be a treatment option worth
future exploration [72]. Current recommendations for the
treatment of nonalcoholic fatty liver disease that results in
the accumulation of fat within the liver, similar to IMAT
accumulation in the muscle, include the combination of diet,
exercise, and in some cases medication [72]. While we are
unaware of any trials examining the effects of medication on
IMAT, the use of anti-inflammatory or othermedications that
have been effective at treating other ectopic fat depots such as
thiazolidinediones may be useful in the treatment of IMAT,
particularly in older frail adults [72].
Large randomized control trials examining the effect of
exercise on decreasing IMAT are limited, though it does
appear that physical activity, at a minimum, may serve as
a preventive strategy to halt the infiltration of IMAT into
muscle [24] and may even decrease IMAT in muscles that
have already undergone this abnormal adaptation [20, 22, 51,
52, 55, 61, 62, 91–94, 96, 97, 99]. The majority of studies that
have demonstrated a decrease in IMAThave been studies that
employed a combination of calorie restriction and aerobic
exercise for at least 6 months [20, 51, 52, 62, 91, 93, 96].
It also appears that resistive exercise alone [94, 101] or in
combination with weight loss [97] or aerobic exercise [55, 61]
may decrease IMAT.
It is theorized that exercise training may access IMAT
as a fuel source during times of increased activity of the
muscle [20, 30]. While speculative, IMAT may be preferen-
tially metabolized as a fuel source to support the increased
demands of the muscle thus resulting in a decrease of IMAT
with long-term activity [20, 30]. While exercise should be
a lifelong activity, to decrease IMAT levels a minimum of
12 weeks of intervention appears to be required to decrease
IMAT, though 6 months may be superior. It is important
to note that exercise interventions have multiple effects on
physiology and the improvements found in these studies
may not be due to a reduction in IMAT. Further research is
8 International Journal of Endocrinology
needed to elucidate the role of decreased IMAT on muscle
and metabolic function as well as the most effective exercise
prescription to target a reduction in IMAT in older adults.
As our population ages and larger number of individuals
with metabolic, muscle, and mobility dysfunction require
effective interventions, there is an increase in the need for
understanding and treating the multiple negative metabolic
and muscle adaptations that may occur. IMAT is now recog-
nized as an important predictor of muscle metabolism and
function and also appears to be a modifiable muscle risk
factor. Exercise and physical activity appear to be effective
countermeasures against increases in IMAT. Future research
should focus not only on the causes and mechanisms of
increased fatty infiltration but also on establishing whether
and how IMAT is involved in the development of the
pathologies discussed aswell as effective intervention regimes
to decrease IMAT.
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